Fluoroquinolone-resistant Streptococcus agalactiae: Epidemiology and mechanism of resistance

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2495-2497

  Wehbeh, Wehbeh ^a,b   Rojas Diaz, Roberto ^a   Li, Xinying ^c   Mariano, Noriel ^a   Grenner, Louise ^a   Segal Maurer, Sorana ^a,b   Tommasulo, Barbara ^a,b   Drlica, Karl ^c   Urban, Carl ^a,b   Rahal, James J ^a,b  

^a NEW YORK HOSPITAL QUEENS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINDAMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HAEMOPHILUS INFLUENZAE; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STREPTOCOCCUS AGALACTIAE;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 21144442067     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2495-2497.2005     Document Type: Article

References (17)

1. Diekema, D. J., J. I. Andrews, H. Huynh, P. R. Rhomberg, S. R. Doktor, J. Beyer, V. D. Shortridge, R. K. Flamm, R. N. Jones, and M. A. Pfaller. 2003. Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci. J. Clin. Microbiol. 41:2659-2661.
2. Farley, M. M., R. C. Harvey, T. Stull, J. D. Smith, A. Schughat, J. D. Wenger, and D. S. Stephens. 1993. A population based assessment of invasive disease due to group B streptococcus in nonpregnant adults. N. Engl. J. Med. 328:1807-1811.
3. Farley, M. M. 2001. Group B streptococcal disease in nonpregnant adults. Clin. Infect. Dis. 33:556-561.
4. Heelan, J. S., M. E. Hasenbein, and A. J. McAdam. 2004. Resistance of group B streptococcus to selected antibiotics, including erythromycin and clindamycin. J. Clin. Microbiol. 42:1263-1264.
5. Henning, K. J., E. L. Hall, and D. M. Dwyer. 2001. Invasive group B streptococcal disease in Maryland nursing home residents. J. Infect. Dis. 183:1138-1142.
6. Kawamura, Y., H. Fujiwara, N. Mishima, Y. Tanaka, A. Tanimoto, S. Ikawa, Y. Itoh, and T. Ezaki. 2003. First Streptococcus agalactiae isolates highly resistant to quinolones with point mutations in gyrA and parC. Antimicrob. Agents Chemother. 47:3605-3609.
7. Li, X., N. Mariano, J. J. Rahal, C. M. Urban, and K. Drlica. 2004. Quinolone-resistant Haemophilus influenzae in a long-term care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase. Antimicrob. Agents Chemother. 48:3570-3572.
8. Murdoch, D. R., and L. B. Reller. 2001. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10 year perspective. Antimicrob. Agents Chemother. 45:3623-3624.
9. Nazir, J., C. Urban, N. Mariano, J. Burns, B. Tommasulo, C. Rosenberg, S. Segal-Maurer, and J. J. Rahal. 2004. Quinolone resistant Haemophilus influenzae in a long term care facility: clinical and molecular epidemiology. Clin. Infect. Dis. 38:1564-1569.
10. NCCLS. 2004. Performance standards for antimicrobial susceptibility testing: fourteenth informational supplement. NCCLS document M100-14. NCCLS, Wayne, Pa.
11. Paterson, D. L. 2004 "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl. 4):S341-S345.
12. Perman, D. C., W. M. El Sadr, L. B. Heifets, E. T. Nelson, J. P. Matts, K. Chirgwin, N. Salomon, E. E. Telzak, O. Klein, B. N. Kreiswirth, J. M. Musser, and R. Hafner. 1997. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 11:1473-1478.
13. Peterson, L. R., and A. Dalhoff. 2004. Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed through improved diagnostic testing? J. Antimicrob. Chemother. 53:902-905.
14. Sambola, A., J. M. Miro, M. P. Tornos, B. Almirante, A. Moreno-Torrico, M. Gurgui, E. Martinez, A. Del Rio, M. Azqueta, F. Marco, and J. M. Gatell. 2002. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962-1998. Clin. Infect. Dis. 34:1576-1584.
15. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
16. Tyrrell, G. J., L. D. Senzilet, J. S. Spika, D. A. Kertesz, M. Alagaratnam, M. Lovgren, and J. A. Talbot. 2000. Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study-1996. J. Infect. Dis. 182:168-173.
17. Wu, J. J., K. Y. Lin, P. R. Hsueh, J. W. Liu, H. I. Pan, and S. M. Sheu. 1997. High incidence of erythromycin-resistant streptococci in Taiwan. Antimicrob. Agents Chemother. 41:844-846.